Business Description
GemPharmatech Co Ltd
ISIN : CNE100005964
Share Class Description:
SHSE:688046: Class ATotal Employee Number:
1,590Compare
Compare
Traded in other countries / regions
688046.China Index Membership
SSE Composite Index IPO Date
2022-04-25Description
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.18 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | 1.33 | |||||
Interest Coverage | 30.05 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 10.99 | |||||
Beneish M-Score | -2.36 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.9 | |||||
3-Year EBITDA Growth Rate | 5.3 | |||||
3-Year EPS without NRI Growth Rate | 3.7 | |||||
3-Year Book Growth Rate | 4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 24.19 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 17.72 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 35.05 | |||||
9-Day RSI | 43.62 | |||||
14-Day RSI | 48.11 | |||||
3-1 Month Momentum % | 0.63 | |||||
6-1 Month Momentum % | 5.75 | |||||
12-1 Month Momentum % | 26.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.58 | |||||
Quick Ratio | 3.4 | |||||
Cash Ratio | 2.27 | |||||
Days Inventory | 86.39 | |||||
Days Sales Outstanding | 179.74 | |||||
Days Payable | 83.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.98 | |||||
Dividend Payout Ratio | 0.31 | |||||
Forward Dividend Yield % | 0.98 | |||||
5-Year Yield-on-Cost % | 0.98 | |||||
Shareholder Yield % | -0.55 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 64.35 | |||||
Operating Margin % | 24.2 | |||||
Net Margin % | 19.23 | |||||
EBITDA Margin % | 23.42 | |||||
FCF Margin % | 19.43 | |||||
OCF Margin % | 30.06 | |||||
ROE % | 7.24 | |||||
ROA % | 5.7 | |||||
ROIC % | 11.33 | |||||
3-Year ROIIC % | -0.93 | |||||
ROC (Joel Greenblatt) % | 20.31 | |||||
ROCE % | 8.44 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 56.53 | |||||
Forward PE Ratio | 49.16 | |||||
PE Ratio without NRI | 49.26 | |||||
Price-to-Owner-Earnings | 217.42 | |||||
PEG Ratio | 4.14 | |||||
PS Ratio | 10.86 | |||||
PB Ratio | 4.07 | |||||
Price-to-Tangible-Book | 4.21 | |||||
Price-to-Free-Cash-Flow | 56.65 | |||||
Price-to-Operating-Cash-Flow | 36.42 | |||||
EV-to-EBIT | 43.42 | |||||
EV-to-EBITDA | 43.42 | |||||
EV-to-Revenue | 10.17 | |||||
EV-to-FCF | 52.32 | |||||
Price-to-GF-Value | 1.14 | |||||
Price-to-Graham-Number | 3.01 | |||||
| Price-to-Net-Current-Asset-Value | 8.19 | |||||
| Price-to-Net-Cash | 18.55 | |||||
Earnings Yield (Greenblatt) % | 2.3 | |||||
FCF Yield % | 1.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GemPharmatech Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 830.61 | ||
| EPS (TTM) (Â¥) | 0.4 | ||
| Beta | 2.3961 | ||
| 3-Year Sharpe Ratio | 0.31 | ||
| 3-Year Sortino Ratio | 0.52 | ||
| Volatility % | 55.78 | ||
| 14-Day RSI | 48.11 | ||
| 14-Day ATR (Â¥) | 2.449489 | ||
| 20-Day SMA (Â¥) | 23.968 | ||
| 12-1 Month Momentum % | 26.94 | ||
| 52-Week Range (Â¥) | 12.89 - 31 | ||
| Shares Outstanding (Mil) | 410 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GemPharmatech Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GemPharmatech Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.190000 Cash Dividend | 2026-06-09 | 17.41 (+2.11%) | ||
| CNY 0.030000 Cash Dividend | 2025-11-20 | 17.29 (-2.76%) | ||
| CNY 0.110000 Cash Dividend | 2025-07-11 | 14.81 (-2.57%) | ||
| CNY 0.030000 Cash Dividend | 2024-11-04 | 13.12 (-0.30%) | ||
| CNY 0.160000 Cash Dividend | 2024-08-07 | 11.72 (+3.53%) |
Show
Entries
GemPharmatech Co Ltd Frequently Asked Questions
What is GemPharmatech Co Ltd(SHSE:688046)'s stock price today?
The current price of SHSE:688046 is ¥22.61. The 52 week high of SHSE:688046 is ¥31.00 and 52 week low is ¥12.89.
When is next earnings date of GemPharmatech Co Ltd(SHSE:688046)?
The next earnings date of GemPharmatech Co Ltd(SHSE:688046) is .
Does GemPharmatech Co Ltd(SHSE:688046) pay dividends? If so, how much?
The Dividend Yield %  of GemPharmatech Co Ltd(SHSE:688046) is 0.98% (As of Today), Highest Dividend Payout Ratio of GemPharmatech Co Ltd(SHSE:688046) was 1. The lowest was 0.16. And the median was 0.48. The  Forward Dividend Yield % of GemPharmatech Co Ltd(SHSE:688046) is 0.98%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on GemPharmatech Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers